IPM Take
The sharp point is that WHO has moved obesity treatment out of the lifestyle-only corner and into chronic disease policy. But the guideline also makes the access problem unavoidable. GLP-1 medicines may change obesity care, but only if countries decide who should be prioritised, how treatment is funded, how long patients are supported and how medication is linked to behavioural and preventive care. Without that machinery, the people most at risk may be the least likely to benefit.
Executive Summary
On 1 December 2025, WHO released its first guideline on GLP-1 therapies for treating obesity as a chronic, relapsing disease. The guideline conditionally recommends long-term GLP-1 therapy for adults living with obesity, excluding pregnant women, and recommends intensive behavioural interventions as part of a comprehensive care approach when GLP-1 therapy is prescribed. WHO defines adult obesity as BMI 30 or higher and names liraglutide, semaglutide and tirzepatide as the agents covered for long-term obesity treatment. WHO also warns that even with rapid production expansion, GLP-1 therapies are projected to reach fewer than 10 percent of people who could benefit by 2030.
Why it matters
- Policymakers: Need transparent prioritisation rules so limited GLP-1 supply reaches people at highest clinical need rather than those with the greatest purchasing power.
- Payers: Must prepare for long-term chronic disease coverage, including medication, behavioural support, monitoring and discontinuation planning.
- Clinicians: Need obesity care pathways that combine medication with risk assessment, comorbidity management, behavioural support and follow-up.
Previously, obesity policy often sat between prevention campaigns, lifestyle advice and fragmented clinical care. Medicines were increasingly visible, but the global policy framework was still catching up.
What has changed is that WHO now frames GLP-1 treatment as part of lifelong, person-centred obesity care. The recommendation is conditional, not a blanket endorsement. WHO explicitly points to uncertainty around long-term safety, treatment maintenance, discontinuation, high cost, health-system preparedness and equity.
The eligibility frame is broad but defined: adults living with obesity, excluding pregnant women, with treatment delivered as part of comprehensive care rather than medication alone. The JAMA summary also makes clear that countries will need evidence-based prioritisation while access, capacity and readiness expand.
The implementation message is direct. Countries now need prioritisation frameworks, fair pricing, regulated prescribing, behavioural support, monitoring and protection against falsified products. Obesity treatment has entered the personalised medicine agenda because access will depend on risk, comorbidity, affordability and health-system readiness, not only BMI.
